Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2003 Sep;74(9):1258–1261. doi: 10.1136/jnnp.74.9.1258

Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996–2000

B Traynor 1, M Alexander 1, B Corr 1, E Frost 1, O Hardiman 1
PMCID: PMC1738639  PMID: 12933930

Abstract

Background: In recent years, there has been a paradigm shift in the method of healthcare delivery to amyotrophic lateral sclerosis (ALS) patients with the emergence of multidisciplinary ALS clinics that cater exclusively for patients with this condition. The impact of multidisciplinary management has not been previously evaluated.

Methods: Using data from the Irish ALS Register, we conducted a prospective, population based study of all ALS cases diagnosed in Ireland over a five year period to evaluate the effectiveness of a multidisciplinary clinic on ALS survival.

Results: Eighty two (24%) patients attended the multidisciplinary ALS clinic, with the remaining 262 (76%) cases followed in a general neurology clinic. The ALS clinic cohort was an average of five years younger (60.1 v 65.6 years) and were more likely to receive riluzole than the general neurology cohort (99% v 61%). The median survival of the ALS clinic cohort was 7.5 months longer than for patients in the general neurology cohort (logrank = 15.4, p < 0.0001). Overall, one year mortality was decreased by 29.7%. Prognosis of bulbar onset patients was extended by 9.6 months if they attended the ALS clinic. Using multivariate analysis, attendance at the ALS clinic was an independent covariate of survival (HR = 1.47, p = 0.02).

Conclusions: ALS patients who received their care at a multidisciplinary clinic had a better prognosis than patients attending a general neurology clinic. The data suggest that active and aggressive management enhances survival, particularly among ALS patients with bulbar dysfunction. The effect of clinic type must be considered in future clinical trials design.

Full Text

The Full Text of this article is available as a PDF (136.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aboussouan L. S., Khan S. U., Meeker D. P., Stelmach K., Mitsumoto H. Effect of noninvasive positive-pressure ventilation on survival in amyotrophic lateral sclerosis. Ann Intern Med. 1997 Sep 15;127(6):450–453. doi: 10.7326/0003-4819-127-6-199709150-00006. [DOI] [PubMed] [Google Scholar]
  2. Aupperle P. M., Coyne A. C. Primary vs subspecialty care: a structured follow-up of dementia patients and their caregivers. Am J Geriatr Psychiatry. 2000 Spring;8(2):167–170. [PubMed] [Google Scholar]
  3. Bradley W. G., Anderson F., Bromberg M., Gutmann L., Harati Y., Ross M., Miller R. G., ALS CARE Study Group Current management of ALS: comparison of the ALS CARE Database and the AAN Practice Parameter. The American Academy of Neurology. Neurology. 2001 Aug 14;57(3):500–504. doi: 10.1212/wnl.57.3.500. [DOI] [PubMed] [Google Scholar]
  4. Brooks B. R. Defining optimal management in ALS: from first symptoms to announcement. Neurology. 1999;53(8 Suppl 5):S1–S21. [PubMed] [Google Scholar]
  5. Brooks B. R. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors. J Neurol Sci. 1994 Jul;124 (Suppl):96–107. doi: 10.1016/0022-510x(94)90191-0. [DOI] [PubMed] [Google Scholar]
  6. Chancellor A. M., Slattery J. M., Fraser H., Swingler R. J., Holloway S. M., Warlow C. P. The prognosis of adult-onset motor neuron disease: a prospective study based on the Scottish Motor Neuron Disease Register. J Neurol. 1993 Jun;240(6):339–346. doi: 10.1007/BF00839964. [DOI] [PubMed] [Google Scholar]
  7. Chiò A., Finocchiaro E., Meineri P., Bottacchi E., Schiffer D. Safety and factors related to survival after percutaneous endoscopic gastrostomy in ALS. ALS Percutaneous Endoscopic Gastrostomy Study Group. Neurology. 1999 Sep 22;53(5):1123–1125. doi: 10.1212/wnl.53.5.1123. [DOI] [PubMed] [Google Scholar]
  8. Corr B., Frost E., Traynor B. J., Hardiman O. Service provision for patients with ALS/MND: a cost-effective multidisciplinary approach. J Neurol Sci. 1998 Oct;160 (Suppl 1):S141–S145. doi: 10.1016/s0022-510x(98)00214-7. [DOI] [PubMed] [Google Scholar]
  9. Cudkowicz M. E., McKenna-Yasek D., Sapp P. E., Chin W., Geller B., Hayden D. L., Schoenfeld D. A., Hosler B. A., Horvitz H. R., Brown R. H. Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis. Ann Neurol. 1997 Feb;41(2):210–221. doi: 10.1002/ana.410410212. [DOI] [PubMed] [Google Scholar]
  10. Lacomblez L., Bensimon G., Leigh P. N., Guillet P., Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet. 1996 May 25;347(9013):1425–1431. doi: 10.1016/s0140-6736(96)91680-3. [DOI] [PubMed] [Google Scholar]
  11. McDonald E. R., Wiedenfeld S. A., Hillel A., Carpenter C. L., Walter R. A. Survival in amyotrophic lateral sclerosis. The role of psychological factors. Arch Neurol. 1994 Jan;51(1):17–23. doi: 10.1001/archneur.1994.00540130027010. [DOI] [PubMed] [Google Scholar]
  12. Miller R. G., Rosenberg J. A., Gelinas D. F., Mitsumoto H., Newman D., Sufit R., Borasio G. D., Bradley W. G., Bromberg M. B., Brooks B. R. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force. Neurology. 1999 Apr 22;52(7):1311–1323. doi: 10.1212/wnl.52.7.1311. [DOI] [PubMed] [Google Scholar]
  13. Moore Dan H., 2nd How useful are retrospective studies in evaluating therapeutic interventions? Amyotroph Lateral Scler Other Motor Neuron Disord. 2002 Mar;3(1):3–3. doi: 10.1080/146608202317576471. [DOI] [PubMed] [Google Scholar]
  14. Silani V., Borasio G. D. Honesty and hope: announcement of diagnosis in ALS. Neurology. 1999;53(8 Suppl 5):S37–S42. [PubMed] [Google Scholar]
  15. Thornton Frank J., Fotheringham Timothy, Alexander Michael, Hardiman Orla, McGrath Frank P., Lee Michael J. Amyotrophic lateral sclerosis: enteral nutrition provision--endoscopic or radiologic gastrostomy? Radiology. 2002 Sep;224(3):713–717. doi: 10.1148/radiol.2243010909. [DOI] [PubMed] [Google Scholar]
  16. Traynor B. J., Codd M. B., Corr B., Forde C., Frost E., Hardiman O. Incidence and prevalence of ALS in Ireland, 1995-1997: a population-based study. Neurology. 1999 Feb;52(3):504–509. doi: 10.1212/wnl.52.3.504. [DOI] [PubMed] [Google Scholar]
  17. Traynor Bryan J., Alexander Michael, Corr Bernie, Frost Eithne, Hardiman Orla. An outcome study of riluzole in amyotrophic lateral sclerosis--a population-based study in Ireland, 1996-2000. J Neurol. 2003 Apr;250(4):473–479. doi: 10.1007/s00415-003-1026-z. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES